0
Skip to Content
K2 Health Ventures
Approach
Team
Portfolio
News
Purpose
Contact
K2 Health Ventures
Approach
Team
Portfolio
News
Purpose
Contact
Approach
Team
Portfolio
News
Purpose
Contact

 All

Therapeutics

Digital Health & Services

Medical Devices & Diagnostics

Other

Featured
Umoja Biopharma
Umoja Biopharma

Clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity.

Werewolf Therapeutics (NASDAQ: HOWL)
Werewolf Therapeutics (NASDAQ: HOWL)

Clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer and other immune-mediated conditions.

Acumen Pharmaceuticals (NASDAQ: ABOS)
Acumen Pharmaceuticals (NASDAQ: ABOS)

Clinical-stage drug development company focused on developing novel targeted therapies for Alzheimer's disease.

MindMed (NASDAQ: MNMD)
MindMed (NASDAQ: MNMD)

Clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders.

Vedanta Biosciences
Vedanta Biosciences

A clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia.

Harpoon Therapeutics (NASDAQ: HARP)
Harpoon Therapeutics (NASDAQ: HARP)

Clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.

89bio (NASDAQ: ETNB)
89bio (NASDAQ: ETNB)

Clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.

Alto Neuroscience (NYSE: ANRO)
Alto Neuroscience (NYSE: ANRO)

Clinical-stage drug development company pioneering precision psychiatry by developing targeted medicines to help patients get better faster.

OncXerna Therapeutics
OncXerna Therapeutics

Clinical-stage precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates.

Aptinyx (NASDAQ: APTX)
Aptinyx (NASDAQ: APTX)

Clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders.

ASLAN Pharmaceuticals (NASDAQ: ASLN)
ASLAN Pharmaceuticals (NASDAQ: ASLN)

Clinical-stage immunology focused biopharmaceutical company developing therapies for atopic dermatitis and asthma.

Corbus Pharmaceuticals (NASDAQ: CRBP)
Corbus Pharmaceuticals (NASDAQ: CRBP)

Clinical-stage drug development company pioneering transformative medicines to treat inflammatory and fibrotic diseases by targeting the endocannabinoid system.

Elevation Oncology (NASDAQ: ELEV)
Elevation Oncology (NASDAQ: ELEV)

Clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers.

Evelo Biosciences (NASDAQ: EVLO)
Evelo Biosciences (NASDAQ: EVLO)

Clinical-stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects

Inozyme (NASDAQ: INZY)
Inozyme (NASDAQ: INZY)

Clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization.

Inspirna
Inspirna

Clinical-stage biopharmaceutical company leveraging a proprietary microRNA-based target discovery platform to develop first-in-class small molecule and antibody cancer therapeutics.

Metacrine (NASDAQ: MTCR)
Metacrine (NASDAQ: MTCR)

Clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases.

Molecular Templates (NASDAQ: MTEM)
Molecular Templates (NASDAQ: MTEM)

Clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics called engineered toxin bodies (ETBs).

Oncorus (NASDAQ: ONCR)
Oncorus (NASDAQ: ONCR)

Clinical-stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies for cancer.

Ribon Therapeutics
Ribon Therapeutics

Clinical stage biotechnology company developing therapeutics targeting stress support pathways.

Surface Oncology (NASDAQ: SURF)
Surface Oncology (NASDAQ: SURF)

Clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment.

TScan Therapeutics (NASDAQ: TCRX)
TScan Therapeutics (NASDAQ: TCRX)

Dedicated to creating life-changing T Cell therapies for patients by unleashing the untapped potential of the human immune system.

VBI Vaccines (NASDAQ: VBIV)
VBI Vaccines (NASDAQ: VBIV)

Commercial-stage biopharmaceutical company developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology.

If you would like to learn more about K2 HealthVentures, would like to suggest or submit an investment opportunity, or are interested in joining our team, please click here to email us.

Contact Us
Copyright© K2 HealthVentures™. All rights reserved.